Sign in
CompletedNo phase

Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor

Key facts

Who runs it
Hospices Civils de Lyon
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
86 people enrolled
Started
4 Feb 2026
Ended
13 Mar 2026
Type of study
Observational, 2 groups
Treatments tested
  • Retrospective collection of health data
  • Phone call to every participant
Record updated
6 April 2026

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Age > 18
  • Heterozygous asymptomatic Factor V Leiden mutation or Factor II mutation, diagnosed before or during pregnancy
  • Delivering between 01/01/2020 and 31/12/2025
  • Patient with French social security rights

Who cannot take part

  • NA

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT).

Read full original descriptionShow less

The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases in the postpartum period, rising up to 80-fold. VTE is a multifactorial condition, and several studies have identified risk factors for DVT during this period. These factors may be related to the patient herself-such as age, overweight, smoking, a personal or family history of DVT, and/or thrombophilia. Factors related to the pregnancy itself and peripartum events-such as preeclampsia, multiple pregnancy, the mode of delivery (emergency or elective cesarean section), and postpartum hemorrhage-have also been identified as DVT risk factors.

Resistance to activated protein C caused by the Factor V Leiden mutation affects about 5% of the population and, in its heterozygous form, increases the risk of VTE by 3- to 10-fold depending on the study, raising the absolute risk to approximately 1 in 400. The heterozygous mutation of the prothrombin (Factor II) gene affects about 2% of the population and increases the risk of VTE threefold. However, although the risk is increased, the absolute risk of VTE remains low (0.5 to 1%).

Regarding prevention, recommendations are heterogeneous and often based on a low level of evidence. In certain situations (e.g., history of provoked thrombosis, moderate thrombophilia), prophylaxis is not always recommended, or its duration is not clearly defined, and the benefit-risk balance remains uncertain.

The main objective of this study is to describe the duration of anticoagulation prescribed after delivery according to the characteristics of patients carrying these mutations and their mode of delivery. The secondary composite objective is to compare two treatment durations (less than 2 weeks vs. 6 weeks) to determine whether a shorter treatment is less effective in preventing deep vein thrombosis, and whether a longer treatment is associated with more adverse effects.

The target population therefore consisted of adult women carrying an asymptomatic heterozygous mutation of Factor V or Factor II, who had been followed up or had consulted at the Hospices Civils de Lyon for obstetric or hematologic evaluation related to this mutation.

Investigators extracted health data of the included patients from the Hospices Civils de Lyon medical software. They also contacted patients by phone to complete data collection, particularly to determine whether they had experienced a deep vein thrombosis within 12 weeks after delivery, or any adverse effects related to anticoagulant therapy.

The 2 groups in the trial

  • 2 weeks or less postpartum thromboprophylaxis

    Patients receiving 2 weeks (or less) preventive anticoagulation with low molecular weight heparin after giving birth

    Treatment: Retrospective collection of health data and Phone call to every participant

  • 6 weeks postpartum thromboprophylaxis

    Patients receiving 6 weeks preventive anticoagulation with low molecular weight heparin after giving birth

    Treatment: Retrospective collection of health data and Phone call to every participant

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Asymptomatic Women With Heterozygous Factor V Leiden ou Factor II Mutation.
Record updated
6 April 2026